SKU: 37289196452

Aliye Bricker, M.D.

Sale price$22.50 Regular price$25.00
Save 10%

Pay in installments of $6.25 with ShopPay, AfterPay and Klarna

Shipping Estimate
USA
  • USA
  • CAN

Ships within 48 hours · Estimated delivery Aug 20 - Aug 25

Promo Codes Available:

For Your Every Summer RSVP, with Code: SUMMER15

Description

Aliye Bricker, M.D.RETpositives founder, our North Star, passed away from Stage IV NSCLC in February 2022. She was deeply committed to finding next generation RET therapies. We continue the fight in her honor and all of our fellow RET warriors as we work together to make RET altered cancer just another chronic disease. "I was already stage IV by the time I was diagnosed in late 2015. I was a 34 year old never smoker with a 4 year old, pregnant with my second daughter

RETpositive’s founder, our North Star, passed away from Stage IV NSCLC in February 2022. She was deeply committed to finding next generation RET therapies. We continue the fight in her honor and all of our fellow RET warriors as we work together to make RET-altered cancer just another chronic disease.

"I was already stage IV by the time I was diagnosed in late 2015. I was a 34-year-old never-smoker with a 4-year-old, pregnant with my second daughter while still working as a full-time physician (Neuroradiologist). When I developed a dry, nagging cough in the last few weeks of my pregnancy, my Obstetrician and I wanted to wait until the delivery to get a chest X-ray to avoid any radiation to my unborn baby. The day after my delivery, my chest X-Ray showed a lung mass and pleural effusions, and I was put on antibiotics for presumed pneumonia (even though I never had a fever). Five days later my effusion was drained, leading to my diagnosis with NSCLC. It had already spread to my brain and bones. This terminal diagnosis came as a complete shock. A quick google search informed me that my chances of being alive in five years were about 1%.

"I started off my maternity leave with gamma knife to my solitary brain metastasis and I started chemotherapy (Carboplatin plus Alimta) right away. I had a pleurex catheter placed for my recurrent effusions which came out eight months later. Luckily for me, my oncologist sent my tumor sample for genetic testing and a RET driver mutation was found. Although there were no RET-targeted treatments at the time of my diagnosis, finding RET was still a source of hope.

"After first-line chemotherapy stopped working, I tried (and failed) immunotherapy,  tried (and failed) one of the earlier multikinase inhibitors (cabozantinib), and I developed liver mets to add to my collection, before losing all of my hair with second-line chemotherapy (Docetaxol plus carboplatin.) By the end of the summer in 2017, I was bald and entirely dependent on oxygen, even at rest, and nearly out of treatment options. When the Selpercatinib trial opened at my institution, the Cleveland Clinic, in September 2017 I was the first to enroll, and within three weeks I was no longer oxygen-dependent. This first-generation RET-targeting tyrosene kinase inhibitor (TKI) gave me my life back and by that October, I was trick-or-treating with my kids (without any supplemental oxygen!).

"I’ve now been on Selpercatinib (Retevmo) for 3.5+ years and counting, and have experienced first-hand that medical research does save lives. Most recently in December 2020 my scans did show some small pleural lesions and a nodule in my lung that have been very slowly progressing, for which I underwent stereotactic radiation in January 2021. Most recent scans were encouraging, and I've learned how important it is to take everything one day at a time. My daughters are now five- and ten-years-old and I'm thankful for every day!"

 

Shipping Notes
  • Free Standard Shipping on $100+ Orders to the USA.
  • Except Preorder products are shipped in 48 hours.
  • Delivery to the USA:
  1. Standard Shipping : 3-10 business days
  • If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
  • We offer a 30-day return/exchange service after receiving.
  • Final sale items are not eligible for returns or exchanges.
  • To process your return/exchange, please contact us at [email protected]
  • Please click here for more details>>> Return & Exchange Policy
SKU: 37289196452

Discover Niche Categories That Outsell

Top-Converting Item to Boost Your Average Order

4.4 ★★★★★
Based on 21 reviews
Sort
Highest Rating
Newest First
Oldest First
Product Reviews
G
Verified Purchase
Greta C. Clere
Phoenix, US
★★★★★ 5
Very well made
Color: Light Khaki, Size: Large
Love this shirt. Fabric is great. My husband needed a dress casual shirt for our granddaughter’s garden party wedding reception This is perfect.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on May 28, 2026
K
Verified Purchase
KariJo
Waukegan, US
★★★★★ 5
Buy it!!
Size: X-Small, Color: Iron Grey
Great for the price! Nice dress shirt for summer! Nice material as well! My son loved it!
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on June 3, 2026
S
Verified Purchase
Shaggy
Bozeman, US
★★★★★ 5
Great for the price
Size: X-Small, Color: Pink
Great shirts for the price. I bought one blue, one pink. I guess it's the way of fashion now, though, but there aren't slits for collar strips to keep it straight, and most shirts I've seen are polyester with spandex. If you need spandex to wear a button down, you should get a larger size, please. Very comfortable, but the test will be Colorado summer with a with a white t underneath, but now very cool and airy.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on May 30, 2025
D
Verified Purchase
David Rojas
Pawtucket, US
★★★★★ 5
Nice fancy shirt
Size: Large, Color: White
Good quality, material and size
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on December 17, 2025
T
Verified Purchase
Twanice Cox
Belleville, US
★★★★★ 5
Great for husky boys
Size: XX-Large, Color: White, Size: XX-Large, Color: White
Perfect fit for my son
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on June 30, 2025

recommand products